Evaluation of Atezolizumab Plus Bevacizumab Versus Modified Lenvatinib Therapy in Child-Pugh A Unresectable Hepatocellular Carcinoma.

Cancer diagnosis & prognosis Pub Date : 2024-03-03 eCollection Date: 2024-03-01 DOI:10.21873/cdp.10297

Michio Kimura, Shiori Yamada, Makiko Go, Satoshi Yasuda, Hidenori Toyoda, Eiseki Usami

{"title":"Evaluation of Atezolizumab Plus Bevacizumab Versus Modified Lenvatinib Therapy in Child-Pugh A Unresectable Hepatocellular Carcinoma.","authors":"Michio Kimura, Shiori Yamada, Makiko Go, Satoshi Yasuda, Hidenori Toyoda, Eiseki Usami","doi":"10.21873/cdp.10297","DOIUrl":null,"url":null,"abstract":"Background/aim: Atezolizumab/bevacizumab (Atez/BV) and lenvatinib (LEN) are the recommended first-line treatments for patients with unresectable hepatocellular carcinoma (HCC). Previous reports have suggested that the tolerability and therapeutic efficacy of LEN could be enhanced by modifying its administration method. Therefore, this study compared the efficacy and safety of Atez/BV, the standard LEN therapy (standard LEN), and modified LEN therapy (modified LEN).Patients and methods: The overall survival (OS) and the rate of discontinuation due to adverse events (AEs) were compared between groups treated with Atez/BV (n=36), standard LEN (n=30), and modified LEN (n=11).Results: Discontinuation due to AEs was required in 22.2%, 23.3%, and 9.1% of patients in the Atez/BV, standard LEN, and modified LEN groups (p=0.485). The median OS for the Atez/BV, standard LEN, and modified LEN groups was 523 [95% confidence interval (CI)=163-818], 382 (95%CI=330-547), and 604 (95% CI=257-656) days, respectively (log-rank test, p=0.949).Conclusion: Atez/BV and the standard and modified LEN regimens showed comparable efficacy and safety.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10905284/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer diagnosis & prognosis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21873/cdp.10297","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Atezolizumab/bevacizumab (Atez/BV) and lenvatinib (LEN) are the recommended first-line treatments for patients with unresectable hepatocellular carcinoma (HCC). Previous reports have suggested that the tolerability and therapeutic efficacy of LEN could be enhanced by modifying its administration method. Therefore, this study compared the efficacy and safety of Atez/BV, the standard LEN therapy (standard LEN), and modified LEN therapy (modified LEN).

Patients and methods: The overall survival (OS) and the rate of discontinuation due to adverse events (AEs) were compared between groups treated with Atez/BV (n=36), standard LEN (n=30), and modified LEN (n=11).

Results: Discontinuation due to AEs was required in 22.2%, 23.3%, and 9.1% of patients in the Atez/BV, standard LEN, and modified LEN groups (p=0.485). The median OS for the Atez/BV, standard LEN, and modified LEN groups was 523 [95% confidence interval (CI)=163-818], 382 (95%CI=330-547), and 604 (95% CI=257-656) days, respectively (log-rank test, p=0.949).

Conclusion: Atez/BV and the standard and modified LEN regimens showed comparable efficacy and safety.

查看原文本刊更多论文

评估阿特珠单抗联合贝伐单抗与改良型仑伐替尼治疗Child-Pugh A型不可切除肝细胞癌的效果

背景/目的：阿特珠单抗/贝伐单抗（Atez/BV）和来伐替尼（LEN）是不可切除肝细胞癌（HCC）患者的推荐一线治疗药物。之前有报道称，通过改变给药方法可以提高来伐替尼的耐受性和疗效。因此，本研究比较了Atez/BV、标准LEN疗法（标准LEN）和改良LEN疗法（改良LEN）的疗效和安全性：比较了Atez/BV治疗组（36例）、标准LEN治疗组（30例）和改良LEN治疗组（11例）的总生存率（OS）和因不良事件（AEs）导致的停药率：Atez/BV组、标准LEN组和改良LEN组分别有22.2%、23.3%和9.1%的患者因AEs而需要停药（P=0.485）。Atez/BV组、标准LEN组和改良LEN组的中位OS分别为523天[95%置信区间（CI）=163-818]、382天（95%CI=330-547）和604天（95%CI=257-656）（对数秩检验，P=0.949）：结论：Atez/BV与标准和改良LEN方案的疗效和安全性相当。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer diagnosis & prognosis

自引率

0.00%

发文量